(Nevada, Las Vegas) The United States, DelveInsight’s, “Hypertrophic Cardiomyopathy – Pipeline Insight, 2023,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hypertrophic Cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Hypertrophic Cardiomyopathy Pipeline Report
-
Over 10+ companies and 10 + pipeline drugs Hypertrophic Cardiomyopathy pipeline therapies are in various stages of development, and their anticipated acceptance in the Hypertrophic Cardiomyopathy market would significantly increase market revenue.
-
Leading Hypertrophic Cardiomyopathy companies developing novel drug candidates to improve include Imbria, Bristol-Myers Squibb, Tenaya Therapeutics, and Lexeo Therapeutics, Inc, BioMarin and many others
-
Promising Hypertrophic Cardiomyopathy pipeline therapies in various stages of development include Aficamten, Ninerafaxstat, TN-201, and many others
Hypertrophic Cardiomyopathy Overview
Hypertrophic Cardiomyopathy is a genetic disorder caused by caused by a change or mutation in one or more genes and is mostly passed on through families. It is a heart muscle disease in which the muscle is thickened (hypertrophic). This thickening typically occurs in the lower left chamber of the heart, called the left ventricle. Thickening of the heart muscle can occur at the septum (the muscular wall that separates the left and right side of the heart), the posterior wall or free wall (outside wall of the left ventricle), the apex (the bottom of the heart) or throughout the entire left ventricle. Most people with HCM have no symptoms or feel stable throughout their life. However, others do have symptoms like breathlessness, chest pain, palpitations, light-headedness, and/or fainting. Some people find that their symptoms worsen in later life. This may be because their heart muscle has slowly become stiffer, making it harder for the heart to pump. There are two types of Hypertrophic Cardiomyopathy including Obstructive, which is the most common type, hypertrophic obstructive cardiomyopathy means the wall (septum) between the left ventricle and right ventricle thickens.
Discover more about the emerging Hypertrophic Cardiomyopathy drugs @ Hypertrophic Cardiomyopathy Treatment Drugs
Hypertrophic Cardiomyopathy Pipeline Therapies and Key Companies
-
Imbria: Aficamten
-
Bristol-Myers Squibb: Ninerafaxstat
-
Tenaya Therapeutics: TN-201
Hypertrophic Cardiomyopathy Pipeline Therapeutics Assessment
DelveInsight’s Report covers around 10 + products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued and inactive candidates
Hypertrophic Cardiomyopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Ophthalmic
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
-
Oligonucleotide
-
Peptide
-
Small molecule
Product Type
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Scope of the Hypertrophic Cardiomyopathy Pipeline Report
-
Coverage: Global
-
Key Hypertrophic Cardiomyopathy Companies: Concert Pharmaceutical, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited, and others
-
Key Hypertrophic Cardiomyopathy Pipeline Therapies: Deuruxolitinib, EQ101, MAX 40070, and others.
Find out more about the Hypertrophic Cardiomyopathy treatment options in development @ Hypertrophic Cardiomyopathy Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services